1. Academic Validation
  2. Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106

Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106

  • J Med Chem. 2022 Jul 14;65(13):9206-9229. doi: 10.1021/acs.jmedchem.2c00403.
Timo Heinrich 1 Carl Peterson 1 Richard Schneider 1 Sakshi Garg 1 Daniel Schwarz 1 Jakub Gunera 1 Anita Seshire 1 Lisa Kötzner 1 Sarah Schlesiger 1 Djordje Musil 1 Heike Schilke 1 Benjamin Doerfel 1 Patrizia Diehl 1 Pia Böpple 1 Ana R Lemos 2 Pedro M F Sousa 2 Filipe Freire 2 Tiago M Bandeiras 2 Emma Carswell 3 Nicholas Pearson 3 Sameer Sirohi 3 Mollie Hooker 3 4 Elisabeth Trivier 5 Rebecca Broome 5 Alexander Balsiger 5 Abigail Crowden 5 Christian Dillon 5 Dirk Wienke 1
Affiliations

Affiliations

  • 1 Merck Healthcare KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany.
  • 2 iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras 2781-901, Portugal.
  • 3 Cancer Research Horizons, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, U.K.
  • 4 MSD, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, U.K.
  • 5 Cancer Research Horizons, 4NW, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, U.K.
Abstract

The dysregulated Hippo pathway and, consequently, hyperactivity of the transcriptional YAP/TAZ-TEAD complexes is associated with diseases such as Cancer. Prevention of YAP/TAZ-TEAD triggered gene transcription is an attractive strategy for therapeutic intervention. The deeply buried and conserved lipidation pocket (P-site) of the TEAD transcription factors is druggable. The discovery and optimization of a P-site binding fragment (1) are described. Utilizing structure-based design, enhancement in target potency was engineered into the hit, capitalizing on the established X-ray structure of TEAD1. The efforts culminated in the optimized in vivo tool MSC-4106, which exhibited desirable potency, mouse pharmacokinetic properties, and in vivo efficacy. In close correlation to compound exposure, the time- and dose-dependent downregulation of a proximal biomarker could be shown.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-138565
    99.27%, YAP1/TAZ-TEAD Inhibitor
    YAP
  • HY-134957
    99.91%, pan-TEAD Auto-Palmitoylation Inhibitor
    YAP
  • HY-134955
    99.26%, TEAD1 Palmitoylation Inhibitor
    YAP
  • HY-147208
    99.82%, YAP/TAZ-TEAD Inhibitor
    YAP